Natural compounds targeting YAP/TAZ axis in cancer: Current state of art and challenges

Aviral Kumar1, Bandari BharathwajChetty1, Mukesh Kumar Manickasamy1

  • 1Cancer Biology Laboratory, Department of Biosciences and Bioengineering, Indian Institute of Technology Guwahati (IITG), Guwahati, Assam 781039, India.

PubMed

Insights

This review explores the YAP/TAZ signaling pathway, crucial in cancer development and progression. It highlights natural compounds as a promising therapeutic strategy to target this axis in cancer treatment.

Area of Science:

  • Oncology
  • Molecular Biology
  • Biochemistry

Background:

  • Cancer is a growing global health issue with limited treatments for advanced stages.
  • Understanding cancer's molecular complexities is key to developing innovative therapeutics.
  • The YAP/TAZ transcriptional coactivators, part of the Hippo signaling pathway, are implicated in development, homeostasis, and oncogenesis.

Purpose of the Study:

  • To review the signaling nexus of the YAP/TAZ axis in cancer.
  • To explore the potential of natural compounds as a therapeutic strategy targeting YAP/TAZ in cancer.

Main Methods:

  • Literature review focusing on YAP/TAZ signaling in cancer.
  • Analysis of the role of YAP/TAZ in cancer stem cell attributes, chemoresistance, and metastasis.
  • Investigation of natural compounds' mechanisms and potential in cancer therapy.

Main Results:

  • YAP/TAZ activation influences cellular behavior, proliferation, and tissue renewal, and is overexpressed in various cancers.
  • YAP/TAZ signaling is linked to cancer stemness, metastasis, and chemoresistance.
  • Natural compounds can modulate multiple genes and pathways, showing potential in cancer management.

Conclusions:

  • The YAP/TAZ axis represents a significant vulnerability in tumors.
  • Natural compounds offer a viable alternative or adjuvant strategy for targeting YAP/TAZ in cancer therapy.
  • Further research into natural compounds could lead to novel cancer treatments.

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.6K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K
Targets for Drug Action: Overview01:26

Targets for Drug Action: Overview

Drugs target macromolecules to modify ongoing cellular processes. Primary drug targets include receptors, ion channels, transporters, and enzymes.
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
6.2K
Drugs that Stabilize Microtubules01:15

Drugs that Stabilize Microtubules

Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...
2.0K
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.7K
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.5K